2025-10-01 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the data you provided.  I will focus on delivering concise summaries and actionable insights.

## RXRX Analysis: Recursion Pharmaceuticals Inc.

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **RXRX Cumulative Return:** -23.20%
*   **VOO Cumulative Return:** 39.55%
*   **Absolute Divergence:** -63.2%
*   **Relative Divergence:** 0.4 (on a scale where 0 is the historical minimum and 100 is the historical maximum)

**Analysis:** RXRX has significantly underperformed the S&P 500. The substantial negative divergence (-63.2%) highlights a considerable gap in returns. A relative divergence of 0.4 indicates performance is near its historical low relative to the S&P 500 within the provided data.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2021-2023  | 22.0%  | 81.0% | 26.0%   | -0.2   | 4.2    |
| 2022-2024  | 11.0%  | 81.0% | -10.0%  | 0.1    | 2.9    |
| 2023-2025  | 19.0%  | 80.0% | -43.0%  | 0.1    | 2.1    |

**Analysis:**

*   **CAGR:** Fluctuating growth rates across the analyzed periods.
*   **MDD:** Consistently high Maximum Drawdown (around 80%), indicating significant risk.
*   **Alpha:**  Alpha has declined from positive to strongly negative, meaning Recursion has gone from outperforming to significantly underperforming its benchmark, especially in the most recent period.
*   **Beta:** Low Beta values suggest RXRX's price movements are not strongly correlated with the overall market.
*   **Cap(B):** Market capitalization has decreased, reflecting investor sentiment and potentially lower growth expectations.

### 2. Recent Stock Price Movement

**Key Numbers:**

*   **Current Price:** 4.83
*   **Last Market Data:** Price: 4.84, Previous Close: 4.91, Change: -1.43%
*   **5-day Moving Average:** 4.809
*   **20-day Moving Average:** 4.7547
*   **60-day Moving Average:** 5.2607

**Analysis:** The stock price is currently below its 60-day moving average, but above the 5-day and 20-day moving averages. The small negative change in the last market data suggests a slight downward trend, but not drastically so.

### 3. Technical Indicators and Expected Return

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 54.01 (Neutral)
*   **PPO:** 0.51 (Positive, but weak)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash" (Very Safe - MRI: 0.90)
*   **Recent (20-day) Relative Divergence Change:** -2.0 (Short-term decline)
*   **Expected Return:** -2047.6%

**Analysis:**

*   **MRI:** Despite the high MRI score suggesting investment, it seems to contradict other negative indicators.
*   **RSI:** Neutral RSI doesn't provide a clear buy or sell signal.
*   **PPO:** The slightly positive PPO suggests a weak upward trend in momentum.
*   **Hybrid Signal:**  Despite the high MRI, the extremely negative expected return requires caution. The algorithm suggests full investment, but the massive negative expected return warrants skepticism.
*   **Change in Relative Divergence:** Indicates short-term underperformance relative to the S&P 500.
*   **Expected Return:** The exceptionally negative expected return is a MAJOR RED FLAG. This suggests significant concerns about the long-term prospects of the stock relative to the S&P 500.

### 4. Recent News & Significant Events

*   **Jim Cramer's Skepticism:**  "I Need to See a Proof of Concept Here" - Highlights uncertainty about the company's progress.
*   **Motley Fool Articles:**  Frame RXRX as potentially risky and question its future prospects.
*   **Nvidia/AI Recycling:**  Raises questions about the sustainability of the AI boom and its potential impact on companies like Recursion.
*   **Short Squeeze Potential:** Suggests some believe the stock might experience a temporary price surge.
*   **Dead-Cat Bounce Speculation:** Indicates potential for a short-term recovery after a significant decline, but not necessarily a long-term turnaround.

**Analysis:** Recent news is overwhelmingly cautious to negative. The focus on risk, the need for proof of concept, and the speculation about short squeezes and dead-cat bounces indicate significant uncertainty and potential downside.

### 4-2. Analyst Opinions

*   **Consensus:**  Neutral
*   **Target Price:** Average: 6.47, High: 10.00, Low: 3.00
*   **Recent Rating Changes:** No specific changes provided.

**Analysis:**  The analyst consensus is neutral. The wide range in target prices reflects differing opinions and high uncertainty surrounding the stock's future value.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue   |
|------------|-------|-----------|
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.5  | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2024-08-08 | -0.4  | 0.01 B$   |
| 2025-08-05 | -0.4  | 0.01 B$   |

**Analysis:**  Consistent negative EPS and relatively low revenue indicate the company is currently unprofitable and relies on funding. The repeated date (2025-08-05) suggests a possible data error.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.02B   | -5.54%        |
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |
| 2024-06-30 | $0.01B   | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2025-06-30 | $0.92B   | -18.70%  |
| 2025-03-31 | $0.93B   | -21.68%  |
| 2024-12-31 | $1.03B   | -17.29%  |
| 2024-09-30 | $0.52B   | -18.27%  |
| 2024-06-30 | $0.58B   | -16.69%  |

**Analysis:**

*   **Revenue & Profitability:** Fluctuating revenue with recent negative or low-profit margins indicates instability. The negative profit margins in some quarters suggest significant operational challenges.
*   **Capital & Profitability:** Declining equity and consistently negative ROE suggest the company is not generating returns on its equity and its financial position is deteriorating.

### 7. 종합 분석 (Overall Assessment)

RXRX presents a high-risk investment opportunity. The company has significantly underperformed the S&P 500, exhibits high volatility (as indicated by MDD), and struggles with profitability. Recent news sentiment is largely negative, with concerns about the company's progress and sustainability.

**Key Concerns:**

*   **Negative Divergence:** The significant underperformance compared to the S&P 500 is a major warning sign.
*   **Negative Expected Return:**  The extremely negative expected return signals a potentially very problematic outlook.
*   **Profitability:** Consistent losses and negative ROE raise concerns about the company's financial viability.
*   **News Sentiment:** Negative news and analyst skepticism add to the uncertainty.

**Recommendation:**

Based on the provided information, a **highly cautious** approach is warranted. The data points to significant risks and challenges for Recursion Pharmaceuticals. While the MRI suggests a high investment recommendation, the data contradicts this. Given the other data, investors should **exercise extreme caution** and conduct thorough due diligence before considering an investment. This stock appears to be suitable only for investors with a very high-risk tolerance and a deep understanding of the biotechnology industry.
